A Phase II Study of NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab (NEOADAPT)
Phase of Trial: Phase II
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Letrozole (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Early breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms NEOADAPT
- 26 Jul 2018 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018.
- 26 Jul 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Jul 2018.
- 30 Sep 2016 According to a Cancer Treatment Centers America media release, status changed from not yet recruiting to recruiting.